720 related articles for article (PubMed ID: 25754633)
1. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
2. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
3. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
4. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
[TBL] [Abstract][Full Text] [Related]
5. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
6. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
8. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
9. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
10. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
11. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
14. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
15. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
17. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
18. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
19. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
